November marked yet another month of strong progress. New municipal rollouts, additional signed agreements, and continued growing interest all confirm that we are firmly establishing ourselves as one of the most attractive options for safe and digital medication management both in Sweden and across our expanding European markets, where interest is rising notably in the Netherlands. We continue to grow in usage, in partnerships, and in geographic presence, building steadily on the foundation laid throughout the year.

We are now working intensively to deliver as many Dosell units as possible before year-end. Each delivery contributes directly to our recurring revenue and is therefore central to meeting our communicated forecasts.

Sweden – More Municipal Rollouts, Strong Network Effects
Two additional municipalities launched Dosell in November, both with highly positive outcomes in a short time. One municipality has already placed an additional order for 15 units, clearly showing how the user experience translates quickly into concrete demand.

As we’ve heard before, the feedback has once again been unanimous:
“It’s so user-friendly to operate, it meets all our needs, and the lightweight design is a big plus!”

In addition, five more municipalities have signed agreements to launch Dosell in December and January. During November, we also presented Dosell to 14 new municipalities, and we’re seeing a strong network effect — more and more reference their neighboring municipalities using Dosell and share positive feedback, which strengthens both our credibility and our pipeline going into 2026.

Norway – First Public Procurement Won
Together with our new partner Vakt og Alarm, we have now won a public procurement in Norway that will bring Dosell to six municipalities starting February 1. This marks an important step in our ambition to establish ourselves in the Norwegian market in 2026, much like we have successfully done in Sweden this year.

Finland – Strong Presence and Growing Awareness
In November, we participated in KOPA 2025, Finland’s largest trade fair for municipal home care and assisted living, together with our partner AddSecure. This gave us the opportunity to present Dosell to a wide range of decision-makers and once again, the response was clear:
“This is exactly the kind of solution we’ve been missing in Finland.”

We have now finalized all technical preparations for launch, including integration with UMO/Enovation, training, and workflow configurations. We are fully ready to begin broader rollouts together with AddSecure, with a tested and integrated technical environment in place.

Iceland – New Market, Strong Partner
In November, we launched our new partnership with Skand in Iceland. Our new partner will work with both public and private sector stakeholders (B2B), as well as directly with consumers (B2C). Skand is a well-established player with strong drive and high ambitions, and we look forward to establishing Dosell in another new market where interest is already evident.

The Netherlands – Continued Growth After the Acquisition
Our Dutch subsidiary continues to grow steadily, and the integration is moving ahead rapidly. The team is working closely with both existing and new customers, and in November we increased the number of active units and initiated deployments with several new care organizations. This growth reaffirms Dosell’s strong position in the Dutch market.

We are simultaneously driving multiple improvement initiatives in packaging, installation, and system integrations — all aimed at enhancing user experience and streamlining implementation. Our local presence continues to prove a strategic advantage, creating business value and strengthening customer relationships. Insights from the Netherlands are already proving valuable as we scale in other European markets.

ADDA – Procurement Reissued
The ADDA procurement process has been reissued following minor revisions — something that is common in larger framework agreements. The new deadline for submissions is January 5. For us, this is simply a shift in timing. Our work continues as planned, and several municipalities have already signaled their intention to procure Dosell once the agreement is in place.

Looking Ahead – A Strong Finish to the Year
As we enter the final month of the year, our focus is on delivering according to plan. On the agenda:

  • New municipal implementations
  • Rollout in five new municipalities in Sweden
  • Preparations for first customers in Norway (launching February 1)
  • Launch of Dosell in Iceland – both B2B and B2C
  • Continued growth in the Netherlands – new customers and more units
  • Ongoing pilot discussions and presentations in Sweden
  • Final submission for the ADDA procurement (January 5)
  • Ongoing technical integrations and support
  • Follow-up from the KOPA trade fair in Finland

Thank You for Your Support – We’re Just Getting Started
We remain a small but highly dedicated team, and our strategy is clearly delivering results. With over 30 municipalities now using Dosell in Sweden, operations launched in five European countries, and a growing stream of new customers and deals, we head into 2026 with both momentum and direction.

Thank you for following our journey.
Together, we are building the future of medication management.

iZafe Group AB (publ.) announces that Board Member Anna Håkansson on 27 November 2025 increased her shareholding in the company through the acquisition of 150,000 shares at a price of SEK 0.69 per share. The shares were acquired through her wholly owned company.

The purchase follows an additional acquisition of 100,000 shares made in October. After the latest transaction, Anna Håkansson’s total holding, via her company, amounts to 250,000 shares in iZafe Group.

Anna Håkansson was elected to the Board at this year’s Annual General Meeting.

“I have chosen to increase my shareholding as I see a clear direction for the company and strong potential in the journey we are now undertaking,” says Anna Håkansson, Board Member of iZafe Group.

iZafe Group AB (publ.) announces that the company has entered into a strategic partnership with Vakt og Alarm, one of Norway’s most established providers of safety and alarm services for the care and welfare sector. Through the partnership, Vakt og Alarm will be responsible for the distribution, installation, and support of the Dosell medication dispenser in Norway, while iZafe Group focuses on product development and deeper integrations with healthcare and welfare systems.

The partnership builds on Dosell’s existing integration with the UMO platform and the upcoming transition to the next-generation UMOcx. This enables fast, secure, and scalable implementation in Norwegian municipalities and meets the growing need for safe and digitalized medication management across the country.

As an early confirmation of the partnership’s strength, iZafe Group and Vakt og Alarm have already secured their first joint procurement in Norway. The procurement covers six municipalities with an initial volume of approximately 100 Dosell units. This represents a significant first deal and an important reference for the continued expansion in the Norwegian market.

The standstill period runs until 28 November, and the agreement is scheduled to enter into force on 1 February 2026.

This initial success clearly demonstrates that iZafe Group’s strategy – combining deep technical integration with strong local presence through partners – is already delivering tangible results in the early stages of the company’s expansion in Norway.

– “We are pleased to initiate this collaboration with iZafe Group and see Dosell as a valuable addition to our range of safety solutions. With Dosell, we can offer our customers a proven and user-friendly solution for secure medication management – fully aligned with our mission to contribute to a safer everyday life for both users and care staff,” says Lillian S Lien, CEO of Vakt og Alarm AS.

With this first joint deal, iZafe Group and Vakt og Alarm are laying the foundation for a long-term and expanding collaboration in Norway. The procurement clearly shows how Dosell can be rapidly implemented and scaled within Norwegian care services and marks the beginning of a broader market establishment.

About Vakt og Alarm
Vakt og Alarm AS was founded in 1990 and is a leading Norwegian provider of safety and alarm services for the care and welfare sector. The company has delivered solutions to more than 250 municipalities across Norway and is headquartered in Etne. With an experienced team and a strong focus on quality and availability, Vakt og Alarm contributes to increased safety for both users and care staff throughout the country.

iZafe Group AB (publ.) has signed a distribution agreement with Skand ehf regarding the launch and sales of the medication dispensing robot Dosell in Iceland. The agreement marks an important step in iZafe Group’s continued Nordic expansion and means that Dosell is now being introduced in another European market with a clear need for safe and automated medication management.

Skand is an established player in medical technology and health services in Iceland, with team that has extensive experience in introducing innovative solutions within both the public and private healthcare sectors. Through this partnership, iZafe Group gains a locally rooted distributor with strong reach into professional care providers as well as the consumer market, creating solid conditions for broad and long-term market penetration.
 
As part of the agreement, Skand has placed an initial order of 300 Dosell units, with delivery scheduled during 2026. This volume is expected to generate an annual recurring revenue (ARR) of approximately SEK 2–3 million when fully activated, depending on the distribution between B2B and B2C.
 
Iceland is characterized by a high degree of digitalization and a strong focus on patient safety and efficient care processes. A recent analysis estimates that around 8,700 people in Iceland receive their medications in pouch packaging, corresponding to just over 13% of the country’s elderly population.
 
Skand has developed a launch plan that combines implementation within healthcare and home care with initiatives aimed at the consumer market. This two-track strategy enables Dosell to be introduced broadly and scalably in Iceland without depending on a single market channel.
 
Public healthcare and home care
The launch begins with selected collaborations within healthcare and home care to establish local reference cases and demonstrate the quality and efficiency gains Dosell provides. The focus is on improved adherence, increased safety and reduced workload for care staff.
 
Consumer and pharmacy market
In parallel, Dosell will be introduced through established sales channels targeting consumers and relatives. Skand´s team has long experience in launching medical technology products in these channels, creating favourable conditions for rapid commercialization and broader market reach.
 
We are very pleased to enter into this collaboration with Skand. Iceland is a market with a high level of innovation and a clear focus on patient safety. With Skand’s local presence and experience, we see strong potential to establish Dosell as a leading solution both in the home and within the healthcare sector. This is another important step in our Nordic expansion strategy,” says Anders Segerström, CEO of iZafe Group.
 
“Dosell represents the future of medication management, and we are excited to deliver this innovation to the Icelandic market. Together with iZafe Group, we aim to make daily life safer and easier for patients, families, and healthcare professionals nationwide”, says Bergur Bergsson CEO of Skand ehf.

iZafe Group AB (publ.) announces today that the company’s Business Unit Manager, Helena Kolvik, has acquired approximately 158,500 B-shares in iZafe, corresponding to a total value of approximately SEK 100,000. The acquisitions were carried out on two occasions, last Friday and today.

The acquisitions underline Helena’s strong commitment to iZafe Group’s operations and her confidence in the company’s continued development and growth. Following the transactions, Helena’s total holding amounts to 297,328 B-shares.

“I see how hard our team works every day, how quickly we are developing, and the strong potential in our market. We are in a very exciting phase, and for me, it feels natural to increase my ownership when I see the direction and opportunities ahead of us.” says Helena Kolvik, Business Unit Manager at iZafe Group.

October has been marked by strong progress on multiple fronts. We continue to grow in Sweden, integrate our operations in the Netherlands, take important steps in Finland and launch a groundbreaking pilot in Spain. With a clear focus on quality, partnerships and execution, we enter the final months of the year well-positioned to reach our goals – and build further momentum heading into 2026.

Sweden – Growing customer base, new pilots and increased visibility
We now have more than 20 Swedish municipalities using or actively testing Dosell – and interest continues to grow month by month. In October,
Several municipalities signed new pilot agreements during the month, scheduled to begin in November and December. We are also seeing increased interest from nursing homes (SÄBO), where Dosell is viewed as a concrete solution to reduce medication errors and strengthen residents’ independence.

To meet the growing demand, we have recruited two new salespeople focusing on the municipal and private care sectors. Their role is to support implementation, follow up on leads and drive continued expansion.

Meanwhile, the ADDA procurement process – Sweden’s first national framework agreement for medication dispensing robots – is now in its final phase. The estimated annual contract value of SEK 200 million highlights a maturing market and confirms Dosell’s strong position heading into 2026.

The Netherlands – Integration and continued growth
Following the acquisition of Thuisapparatuur Nederland B.V., our focus has been on fully integrating operations into the Group. The Dutch team has maintained close customer engagement, participated in fairs, onboarded a new customer, and increased volumes with existing ones. We have also initiated new platform integrations and are working on improved packaging to further enhance the user experience.

Dosell is currently in use across more than 30 care organisations in the Netherlands – Europe’s most mature market for medication dispensing robots. Yet growth potential remains significant: over 600,000 people in the country receive medications in pouch packaging, but only around 17,000 medication dispensers are currently in operation. Our solution, developed in this complex environment, is now both technically advanced and highly user-friendly – positioning us strongly to lead the next phase of market growth.

Finland – Strong interest and technical readiness
Together with our partner AddSecure, we have completed all preparatory work ahead of the rollout to existing customers. This includes full integration with the leading UMO/Enovation care platform, training materials, system flows, and pilot testing.

Interest from both private care providers and public welfare areas is very high – Dosell is seen as a concrete and sought-after solution to improve adherence, reduce deviations, and free up time for care staff.
Next week, we will participate in Finland’s largest home care and assisted living trade fair – KOPA 2025 – together with AddSecure, further strengthening our local presence and enabling key customer dialogues.

Spain – Pharmacy launch with Ti Medi
In Spain, we are taking the next step together with our partner Ti Medi, who collaborates with over 1,600 pharmacies that serve more than 200,000 patients receiving pouch-packed medications.

In November, we are launching an initial pilot across approximately 10 pharmacies where Dosell will be physically available in-store. Customers can easily bring Dosell home and register their subscription digitally. The launch will be supported by Black Friday and holiday campaigns, with the goal of establishing a new, safe, and accessible solution for home-based medication management.

The concept of medication dispensers is new to the Spanish market, but with Ti Medi as our partner, we have strong local reach and the right channels to engage both patients and families.
They have also begun promoting the concept in their operations in Portugal and France, where Dosell is now being introduced via trade fairs and local initiatives. The next step will be Italy, where a similar rollout is planned.

Finance & Forecast – On track
Our financial performance in Q3 shows that we’ve established a stable and scalable business model based on recurring revenues. At the beginning of Q4, our ARR reached approximately SEK 7 million – a fourfold increase since the start of the year – and we remain on track to meet our target of SEK 10 million ARR during Q4. The recently acquired Dutch company generated approximately SEK 1 million in revenue during Q3, which was not consolidated but will contribute from Q4 onwards.

At the same time, we’ve improved our cost structure, strengthened cash flow, and created a better foundation for long-term profitable growth. EBITDA improved significantly compared to the same period last year, despite lower overall revenues – a clear sign of increased operational efficiency.

Looking ahead – Key focus areas through year-end
We are now entering the most intense period of the year. Our focus for November and December includes:

  • Finalisation and submission of the ADDA procurement (deadline: 10 November)
  • Onboarding of additional municipalities in Sweden
  • Expanded outreach to nursing homes (SÄBO) and broader engagement with the private care sector
  • Continued product demos and pilot discussions with municipalities
  • Ongoing integration and coordination of operations in the Netherlands
  • Launch and evaluation of the pharmacy pilot in Spain
  • Continued dialogue with new potential partners across Europe

Thank you for your trust – building the future of medication management
We are still a small team – but a highly dedicated one. With a stronger offering, growing recurring revenues, and rapid international expansion, we are entering 2026 with the right conditions to continue delivering – both in the market and toward our strategic goals.

Thank you for following our journey.
We’re only just getting started.

iZafe Group AB (publ.) today, November 3, presents its report for the third quarter.

Summary of financial development

  • Total net revenue for the quarter amounted to 1,102 TSEK (2,031) and consisted entirely of recurring license revenues, with no hardware sales during the period. This stands in clear contrast to the same quarter last year, when revenues were largely derived from hardware sales. The development demonstrates that iZafe has now successfully established a scalable and stable business model based on recurring revenues. At the beginning of the fourth quarter, the company’s ARR amounted to approximately 7 MSEK — a fourfold increase since the start of the year — and the company remains well on track to reach 10 MSEK in ARR during Q4, which will be reflected in the next period. According to the purchase price allocation, the acquired company had net revenue of approximately 1 MSEK that was not consolidated in Q3 but will contribute to revenues in future reports.
  • Operating result (EBIT) for the quarter amounted to -3,273 TSEK (-4,148).
  • Earnings before depreciation and amortization (EBITDA) for the quarter amounted to -2,297 TSEK (-3,166), representing a clear improvement despite lower net sales compared with the same period last year. The improvement reflects a more efficient cost structure and a strengthened focus on profitable growth.
  • Result after financial items for the quarter amounted to -3,537 TSEK (-4,955).
  • Cash flow from operating activities for the quarter amounted to -2,890 TSEK (-2,913).
  • Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
  • Equity per share at the end of the period amounted to 0.05 SEK (0.06).
  • The equity ratio at the end of the period was 41.0% (58.0%).

Significant events during the quarter

  • iZafe Group AB has acquired its exclusive distributor in the Netherlands, Thuisapparatuur Nederland B.V., which now becomes a wholly owned subsidiary under the name Dosell B.V. The acquisition strengthens growth, margins, and cash flow and is carried out without any dilution for shareholders. Through this transaction, iZafe estimates that the target of reaching an ARR of 10 MSEK can be achieved already in Q4 2025, earlier than planned, while the company now receives the full revenue from the sale of Dosell in the Dutch market — Europe’s largest and fastest-growing market for digital medication management.
  • iZafe Group AB has signed an agreement with AddSecure Smart Care Oy for the distribution of the medication-dispensing robot Dosell in Finland. The partnership provides iZafe with access to a well-established player in the welfare technology sector and marks a strategic step in the company’s international expansion, aiming to meet the growing demand for safe and efficient medication management in the home.
  • iZafe Group AB has launched an exclusive shareholder offer in which private individuals holding shares valued at a minimum of 50,000 SEK are offered a complimentary Dosell unit with a subscription. The initiative aims to reward shareholder loyalty and provide more people with the opportunity to experience the benefits of the company’s solution for safe and reliable medication

Significant events after the end of the quarter

  • iZafe Group AB announces that the company’s board members have jointly acquired 156,000 Class B shares at an average price of approximately 0.55 SEK per share. The acquisition underscores the board’s shared commitment and strong confidence in the company’s strategy and future growth.

CEO’s comment
We enter the final quarter of the year with strong momentum, rapid growth, and a business model now fully built on recurring revenues. Revenue now consists entirely of subscription income, providing stability, predictability, and scalability as the number of active Dosell units continues to increase.

At the start of the year, our Annual Recurring Revenue (ARR) was approximately 1.7 MSEK. At the beginning of the fourth quarter, ARR had reached around 7 MSEK — a fourfold increase in less than nine months. The growth rate continues to accelerate month by month, and we expect ARR to increase by at least 1 MSEK per month for the remainder of the year. The recently completed acquisition in the Netherlands further strengthens this development, with the acquired company having net revenue of approximately 1 MSEK that was not consolidated in Q3 but will contribute to revenues in upcoming reports. This clearly demonstrates that our strategy is working, that the market is growing rapidly, and that we offer a solution that truly makes a difference.

Sweden – a growing customer base and strong pipeline
During the autumn, demand for Dosell has increased significantly, and we are now experiencing strong momentum in the Swedish market. Several municipalities that conducted pilot projects earlier in the year have transitioned to full-scale operations, while an increasing number of municipalities are initiating Dosell as part of their regular medication management routines.

To meet the growing interest, we have strengthened our team with an additional sales representative focused on following up on incoming inquiries, developing leads, and driving sales to new municipalities. We currently have several municipalities ready to start pilot projects with Dosell, and additional quotations have already been submitted to enable procurement once the upcoming ADDA tender becomes active. This tender, with a new submission date of November 10, is a strategically important milestone with the potential to reshape the digital medication management market in Sweden – and Dosell is well positioned to take a leading role in this transformation.

We continue to sell both directly and through our partners, allowing us to reach more customers faster and further broaden our customer base. The combination of strong incoming demand, proven results from existing installations, and close collaboration with partners provides a solid foundation for continued growth.

The Netherlands – a strategic acquisition that strengthens the group
During the quarter, we completed the acquisition of our former distributor in the Netherlands, which now operates under the name Dosell B.V. The acquisition was a natural and strategically important milestone – both to strengthen profitability and to deepen our connection to the market. The Dutch team has quickly integrated into our organization and is already contributing to continued growth, improved margins, and stronger cash flows.

With this step, we have taken control of one of our most successful markets and laid the foundation for further expansion in the Benelux region. The combination of local engagement and centralized management allows us to grow faster, more efficiently, and with higher quality.

Focus on Dosell – while Pilloxa is ready to scale
Throughout the year, we have chosen to focus entirely on ensuring Dosell’s success. It has proven to be the right decision – the product has now been established as a leading solution for safe medication management, and we are seeing the results in the form of growing revenues and strong confidence from both partners and customers.

At the same time, there is significant potential in Pilloxa, our regulatory-approved platform for digital patient support programs. Pilloxa already has active customers and collaborations within the pharmaceutical industry, and we see great opportunities to further develop this business area in 2026. With the financial strength generated by Dosell’s growth, we will be able to dedicate more time and resources to scaling Pilloxa going forward.

While Dosell provides safety and reliability in the home, Pilloxa enables digital patient support and data-driven follow-up — together addressing the entire healthcare chain.

Looking Ahead – Strong Growth and Increasing Cash Flows
We stand stronger than ever. Our growth is now entirely driven by recurring revenues, our business model is proven to be scalable, and we have established a solid foundation across multiple markets. Going forward, our focus is on continuing to grow rapidly yet profitably, building cash flow, and ensuring that iZafe secures a leading position in Europe for digital medication management.

Our improved cost structure and growing share of recurring revenues provide us with a solid foundation to continue expanding in a controlled and sustainable way. By maintaining a focus on profitable growth and efficient resource utilization, we can continue investing in our key markets while creating long-term value for our shareholders.

Strategic Partnerships for European Expansion
Earlier this year, we signed a Letter of Intent with the German company JDM Innovation GmbH, part of the PHOENIX group – Europe’s leading player in pharmaceutical distribution and pharmacy operations. The aim of the collaboration is to integrate our medication dispenser Dosell with JDM’s Smila into a shared platform for home medication management.

The dialogue around this partnership is ongoing and remains highly relevant. With PHOENIX group’s presence in 29 European countries, there is a strong foundation for future expansion. We see great opportunities in combining our technology with their logistics and distribution network, which could accelerate the rollout of Dosell in new markets across Europe.

Expansion on Multiple Fronts
In parallel with our strong development in Sweden and the Netherlands, we continue to strengthen our position in other European markets together with our partners. In Finland, we are working closely with AddSecure Smart Care to promote the adoption of digital medication management within healthcare and social care, while our collaboration with Ti Medi in Spain focuses on broadening our market presence and making Dosell available to consumers.

At the same time, several dialogues and proposal processes are underway to establish Dosell in additional European countries, where we are seeing rapidly growing interest in secure, connected, and scalable solutions for medication management at home. This demand confirms that we are in the right place at the right time – and that our technology addresses a genuine need in both public and private healthcare.

We are now in a position where growth is accelerating on all fronts. With a strong product portfolio, a proven business model, strategic partnerships, and a dedicated team, we enter 2026 with full focus on delivering on our goals and solidifying our position as the leading provider of digital medication management in Europe.

I would like to extend my sincere thanks to our entire team, our partners, and our shareholders for your commitment and trust. Together, we are building the future of medication management – and we are only at the beginning of the journey.

Anders Segerström
Chief Executive Officer, iZafe Group

iZafe Group AB (publ) announces that, in accordance with the resolution of the 2025 Annual General Meeting, the company’s three largest shareholders as of 30 September 2025 have appointed a Nomination Committee for the 2026 Annual General Meeting. The next AGM will be held on 28 May 2026.

The Nomination Committee consists of:

  • Patrik Björn, private shareholder and representative of Gästrike Nord Invest AB, with a total holding of 105,800,000 shares (28.97 percent)
  • Stefan Wård, private shareholder with 42,454,090 shares (11.6 percent), serving as Chair of the Nomination Committee
  • Eva Redhe, private shareholder with 20,034,254 shares (5.5 percent)

In total, the Nomination Committee represents 168,288,344 shares, corresponding to approximately 46.08 percent of the share capital and votes in iZafe Group AB.

The Nomination Committee’s mandate is to propose the composition of the Board of Directors, Board fees, auditor, and the Chair of the 2026 AGM.

“We are very pleased to have an engaged and capable Nomination Committee composed of our largest owners. This strengthens our focus on long term value creation and the company’s continued expansion,” says Anders Segerström, CEO of iZafe Group.

The Nomination Committee begins its work as iZafe Group continues to grow rapidly and strengthen its position in digital medication management, in line with the company’s focus on improving health and well being through innovative solutions.

Shareholders who wish to submit proposals to the Nomination Committee may do so via email to .

September marked the start of an intense autumn where several important developments have significantly strengthened our position. Most notably, the strategic acquisition of Thuisapparatuur Nederland B.V., our Dutch distributor. This means that the entire revenue from existing customers in the Netherlands now accrues directly to iZafe Group, compared to previously when we only received a portion of the license income. The deal provides a significant boost to our ARR and improves the Group’s margins.

At the same time, we are taking over customer relationships, contracts, inventory and three dedicated employees – giving us full control of Europe’s most mature and established market for medication dispensers, where Dosell is already used by over 30 care organizations. The collaboration has already made Dosell more technically advanced and user-friendly – something that now strengthens our ability to expand faster into new markets.

Although the Netherlands has around 17,000 medication dispensers in operation, over 600,000 people receive their medicines via multidose sachets – showing that the market is still only at the beginning of its potential. The acquisition makes us more present, faster and better equipped to take the next step.

ADDA – a breakthrough on the Swedish market
Sweden’s first national procurement for medication dispensers has now been published by ADDA. Estimated annual value: SEK 200 million. This creates a clear structure for municipalities to implement medication dispensers – and confirms that the market is maturing.

Several municipalities have already expressed interest in starting pilots with Dosell this autumn, to later call off via the new framework agreement. Even though allocation is yet to come, this is an important development that increases Dosell’s visibility and creates better conditions ahead of 2026.

Sweden – more municipality launches and growing interest
Two new municipalities launched Dosell in September. A third launch has been moved to October – along with two additional municipality launches. We are careful to ensure that every start-up takes place only when the entire organization is ready, to achieve the best possible results and happier users.

We have conducted 10 digital presentations and are in contract discussions with two new municipalities. We also held our first international Partner Day in Stockholm with participants from five countries – providing valuable insights and strengthened collaboration across markets.

Finland – easier implementation thanks to new integration
Our partner AddSecure has quickly established Dosell as a relevant solution in the Finnish market. Through a new integration with UMO/Enovation – one of the most widely used care platforms in Finland – Dosell can now be implemented without replacing existing systems. This has generated strong interest from both private and municipal actors.

Italy – new legislation opens the market
Dosell requires medicines to be packaged in multidose sachets – something that until now has only been legal in certain regions of Italy. After several years of work by our partner, September brought a historic breakthrough: it is now legal to package medicines in multidose sachets throughout Italy.

This is a crucial prerequisite for Dosell to be launched widely in the country. Even though it will take time before large volumes build up, we now have for the first time the opportunity to truly establish ourselves in a market with great future potential.

Looking ahead – an intense quarter awaits
We are now entering the most eventful quarter of the year. In October we will focus on:

  • Submitting to the ADDA procurement (deadline 30 October)
  • Three new municipality launches plus a pilot with 20 Dosell units (with potential to scale to 150–200)
  • 10 new presentations for Swedish municipalities
  • Participation at Äldreomsorgsdagarna in Stockholm with our partner Zafe Care Systems AB
  • Dialogue with a major private operator within elderly care (SÄBO)
  • Finalizing agreements with two new potential partners in Europe
  • Continued technical development in the Netherlands, including new integrations with platforms used by care providers
  • Increased focus on customer satisfaction in the Netherlands, aiming to further strengthen deliveries, onboarding and support for both existing and new customers

We’re building something big – together
We are still a small team – but a very dedicated one. Through the acquisition in the Netherlands, we have strengthened our organization, increased our ARR and improved our profitability.

As communicated in connection with the acquisition, we now estimate that our ARR target of SEK 10 million can be reached already in Q4 2025 – earlier than our previous forecast. At the same time, both ADDA and the acquisition in the Netherlands lay a strong foundation to accelerate reaching future targets.

Thank you for following our journey.

We’re only at the beginning.

iZafe Group AB (publ.) announces that the company’s board members have collectively acquired 156,000 B-shares in the company at an average price of approximately SEK 0.55 per share.

“The fact that the entire board has chosen to increase its ownership is a clear signal of our shared commitment and confidence in iZafe’s strategy and future. We see great potential in the company’s continued development and, through our investments, want to demonstrate that we fully support the path that has been set out,” says Richard Wolff, Chairman of the Board of iZafe Group.

Webbdesign av Comlog Webbyrå Stockholm